If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
53.00    -0.50 (-0.93%)
Bid:
52.00
Ask:
54.00
Spread: 2.00 (3.846%)
Market Cap: £14.82m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Office move and Related Party Transaction

30 Jun 2025 07:00

RNS Number : 8284O
EMV Capital PLC
30 June 2025
Β 

Strictly embargoed for: 07.00 a.m. on 30 June 2025

Β 

EMV CAPITAL PLC

("EMVC", "Group" or "the Company")

Β 

Office move and Related Party Transaction

Β 

EMV Capital Plc (AIM: EMVC), the deep tech and life sciences VC investment group, announces it has entered into a licence agreement (Licence Agreement) with AB Group Limited (AB Group) relating to its shared office space with AB Group.

Β 

Pursuant to the terms of the Licence Agreement, the Company has agreed to share office space with AB Group at an annual rent payable by the Company to AB Group of between c.Β£49,000 and c.Β£66,000 depending upon available rent free amounts passed on to the Company by AB Group from its landlord. In addition to rental amounts, the Company has agreed to pay AB Group a 51.5 per cent. proportion of all service charges, business rates, utilities and other charges associated with the office space, anticipated to be c.Β£52,000 per year. AB Group is not charging the Company an uplift on the actual costs of its rent and other costs. The Company has agreed a minimum period of occupancy through to 31 December 2027 (or sooner if the lease between AB Group and its landlord terminates), with either party being able to terminate upon three months' notice for any longer tenure. All other terms of the Licence Agreement are of a customary nature.

Β 

AB Group is wholly owned by Melvin Lawson, who is currently interested in c.14.54 per cent. of the issued share capital of EMVC, and as such a substantial shareholder of the Company. Accordingly, the entry into the Licence Agreement represents a related party transaction in accordance with Rule 13 of the AIM Rules for Companies.

Β 

The Directors, excluding Dr Ilian Iliev by reason of his concert party relationship with Melvin Lawson, consider, having consulted with the Company's nominated adviser, Panmure Liberum Limited, that the terms of the Licence Agreement are fair and reasonable in so far as the Company's shareholders are concerned.

Β 

For the avoidance of doubt, the Company's registered office remains unchanged at c/o Azets, Burham Yard, London End, Beaconsfield, Buckinghamshire, HP9 2 JH.

Β 

The person responsible for arranging the release of this announcement on behalf of the Company is Ed Hooper, Executive Director and General Counsel of the Company.

Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Β 

Β 

For more information, please contact:

Β 

EMV Capital plc

via Rosewood

Β 

Ilian Iliev, CEO

Β 

Β 

Β 

Panmure Liberum LimitedΒ (NOMAD and Broker)

+44 (0)20 7886 2500

Β 

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Β 

Β 

Rupert Dearden (Corporate Broking)

Β 

Β 

Β 

RosewoodΒ (Financial PR)

+44 (0)20 7653 8702

John West /Β Llewellyn Angus / Lily Pearce

Β 

Β 

About EMV Capital plc (EMVC)

Β 

EMV Capital plc, , is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

Β 

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early stage IP-rich companies.

Β 

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

Β 

Β· capital-efficient investments through Group balance sheet;

Β· fund management of the Evergreen EIS and Martlet Capital Funds;

Β· syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Β 

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

Β 

www.emvcapital.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCBUGDLBXDDGUR
12
Date   Source Headline
1st Jul 20267:00 amRNSPortfolio Update: Glycotest and ProAxsis
17th Jun 20262:32 pmRNSResult of AGM
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.